EU nod for Lilly's Cyramza in stomach cancer
This article was originally published in Scrip
Executive Summary
Lilly's VEGFR-2 binding monoclonal antibody Cyramza (ramucirumab) has been approved by the European Commission for advanced stomach cancer.